ARUNA HULME: Open Payments
NPI 1952618332 · WINSTON SALEM, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,906 in 175 payments from 18 companies in 2025. Trend: 2023 $3,526 · 2024 $4,298 · 2025 $3,906
Food & beverage: $3,906
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 38 | $742 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $543 |
| ABBVIE INC. | 16 | $431 |
| Neurocrine BioSciences, Inc. | 17 | $395 |
| Otsuka America Pharmaceutical, Inc. | 14 | $339 |
| E.R. Squibb & Sons, L.L.C. | 16 | $269 |
| Lundbeck LLC | 10 | $261 |
| Axsome Therapeutics, Inc. | 13 | $214 |
| Teva Pharmaceuticals USA, Inc. | 11 | $169 |
| Bausch Health US, LLC | 8 | $145 |
Products named: REXULTI, CAPLYTA, VRAYLAR, INGREZZA, ARISTADA, COBENFY, VIVITROL, Auvelity.
Industry payments across NC — which companies pay providers there.
